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ABSTRACT
Background In the USA, genetically admixed
populations have the highest asthma prevalence and
severe asthma exacerbations rates. This could be
explained not only by environmental factors but also
by genetic variants that exert ethnic-s pecific effects.
However, no admixture mapping has been performed
for severe asthma exacerbations.
Objective We sought to identify genetic variants
associated with severe asthma exacerbations in
Hispanic/Latino subgroups by means of admixture
mapping analyses and fine mapping, and to assess
their transferability to other populations and
potential functional roles.
Methods We performed an admixture mapping
in 1124 Puerto Rican and 625 Mexican American
children with asthma. Fine-mapping of the
significant peaks was performed via allelic testing of
common and rare variants. We performed replication
across Hispanic/Latino subgroups, and the
transferability to non-Hispanic/Latino populations
was assessed in 1001 African Americans, 1250
Singaporeans and 941 Europeans with asthma. The
effects of the variants on gene expression and DNA
methylation from whole blood were also evaluated
in participants with asthma and in silico with data
obtained through public databases.
Results Genomewide significant associations of
Indigenous American ancestry with severe asthma
exacerbations were found at 5q32 in Mexican
Americans as well as at 13q13-q13.2 and 3p13 in
Puerto Ricans. The single nucleotide polymorphism
(SNP) rs1144986 (C5orf46) showed consistent
effects for severe asthma exacerbations across
Hispanic/Latino subgroups, but it was not validated
in non-Hispanics/Latinos. This SNP was associated
with DPYSL3 DNA methylation and SCGB3A2 gene
expression levels.
Conclusions Admixture mapping study of asthma
exacerbations revealed a novel locus that exhibited

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Admixed minorities in the USA, including

Hispanic/Latino subgroups, show
disproportionate rates of asthma and asthma
exacerbations compared with European-descent
populations, but no study has assessed the
contribution of genetic variation to asthma
exacerbations by admixture mapping.

WHAT THIS STUDY ADDS
⇒ Admixture mapping analysis of severe asthma

exacerbations in Hispanics/Latinos revealed a
functional genetic variant with ethnic-specific
effect over two biologically plausibly genes
implicated in this trait (DPYSL3 and SCGB3A2).

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ Our findings have prioritised novel gene targets

for future research in asthma.

Hispanic/Latino-s pecific effects and regulated
DPYSL3 and SCGB3A2.

INTRODUCTION

Asthma is a chronic inflammatory disease that
shows remarkable heterogeneity by ethnicity and
may result from the complex interplay between
environmental, behavioural and genetic factors.1 In
fact, genetic ancestry is a critical factor for asthma
susceptibility.2 In the USA, asthma prevalence is
the highest in Puerto Ricans (14.0%), followed
by African Americans (10.7%), and the lowest in
Mexican Americans (5.4%) and Asian Americans
(4.5%).3 However, racial/ethnic disparities are not
limited to asthma prevalence, since Puerto Ricans
and African Americans also show the highest
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rates of asthma-related emergency room or urgent care visits.4
Asthma exacerbations, defined as those events requiring urgent
asthma care, hospitalisations or administration of systemic corticosteroids, contribute to the large healthcare expenditures of
asthma5 and asthma-related deaths.6 Moreover, exacerbations
impair individuals’ quality of life7 and long-term lung function.8
Although environmental exposures, such as viral infections or air
pollution, are known triggers for asthma exacerbations, several
genetic loci for asthma exacerbations have been successfully
uncovered through genomewide association studies in Hispanic/
Latino populations.9–11
Hispanics/Latinos are American admixed individuals with
variable influences from Indigenous American, African and European populations (ie, African ancestry is higher in Puerto Ricans,
whereas Indigenous American ancestry is higher in Mexicans).12
In a scenario where a trait shows differential rates in admixed
individuals, admixture mapping in the most affected populations
can identify genetic variants associated with that trait. In fact,
mapping causal variants by long-range linkage disequilibrium
decreases multiple testing burden and can be coupled with functional approaches to prioritise genetic variants that could have
population-specific effects.
Given the disparities in asthma prevalence and outcomes,
multiple studies have leveraged locus-specific genetic ancestry
to identify genetic variants associated with asthma-
related
outcomes.12–15 However, no admixture mapping of severe
asthma exacerbations has been performed to date. We hypothesised that genetic variation might partially explain the ethnic
differences in severe asthma exacerbations among Hispanics/
Latinos. Hence, we aimed to identify novel genetic variants associated with severe asthma exacerbations by admixture mapping
in Hispanic/Latino children and youth with asthma. We then
sought to evaluate the potential functional consequences of
those genetic variants and attempted to validate them in non-
Hispanic/Latino populations.

METHODS

A full description of the methods with a graphical summary of
the workflow (online supplemental figure E1) is found in online
supplemental material.

Discovery population

We analysed genotypes from Puerto Ricans (n=1124) and
Mexican Americans (n=625) from the study of Genes-
Environment and Admixture in Latino Americans (GALA II),
a case–control study of asthma in Hispanics/Latinos aged 8–21
years old recruited in the USA and Puerto Rico between 2006
and 2014. GALA II was approved by the Human Research
Protection Program Institutional Review Board of the University of California, San Francisco (USA), and participants/parents
provided written assent/consent, respectively. Participants were
eligible if they reported four Hispanic/Latino grandparents.
Asthma cases were diagnosed by a physician, had asthma symptoms and reported use of controller or rescue medication in the
2 years preceding enrolment.16 Severe asthma exacerbations
were defined as the presence of any of the following events in
the past 12 months: use of oral corticosteroids, asthma-related
hospitalisations or unscheduled asthma care.17 Treatment category, defined following the Expert Panel Report 3 (EPR-
3)
guidelines for the diagnosis and management of asthma,18 was
used as a proxy for asthma severity. Three levels were defined
based on the use of short beta-agonists (step 1); one inhaled
corticosteroid, leukotriene inhibitor or theophylline tablet (step
2

2); or more than one or a combination of an inhaled corticosteroid, leukotriene inhibitor; or theophylline tablet or a combination of inhaled corticosteroids and long-beta agonists (step 3).

Whole-genome sequencing data generation and processing

Whole-genome sequencing (WGS) was conducted on a HiSeq X
system (Illumina, San Diego, California). Data generation and
quality control (QC) are described in online supplemental material. Genotypes used in this study were based on TOPMed freeze
8 data.

Local and global ancestry estimation

The ancestral reference panel for ancestry estimation included
90 HapMap phase II Europeans (CEU), 90 Africans (YRI) and 71
Native Americans (NAM).19 Local ancestry was estimated with
RFMIX V.220 based on biallelic single nucleotide polymorphisms
(SNPs) that passed the QC procedures of the WGS pipeline
and that overlapped with the reference panel (402 838 SNPs).
Global ancestry was calculated as the genomewide average of
local ancestry.

Admixture mapping in Hispanics/Latinos

The association of asthma exacerbations and the number of
copies of African, European and Indigenous American local
ancestry (0, 1 or 2 copies) at each SNP analysed was tested
separately in Hispanic/Latino subgroups. This was performed
through logistic regression models with correction for global
ancestry, age, sex and treatment category (as a proxy for asthma
severity). To account for multiple comparison testing, the final
effective number of tests was defined as the sum of the two largest
effective numbers of ancestry blocks, consistent with Horimoto
et al21, and as detailed in online supplemental material.

Fine-mapping and replication

Fine-mapping of variants with minor allele frequency (MAF)
≥1% within the genomewide significant admixture mapping
peaks was performed with correction for the same covariates
used in the admixture mapping. To correct for multiple comparison, an adjusted threshold of significance was defined as p≤0.05/
number of effective tests. To evaluate whether independent SNPs
account for the admixture mapping signal, we performed stepwise conditional regression analyses adjusting the association of
local ancestry by the allele dosage of associated SNPs. Interaction of local ancestry on the association of the SNPs with exacerbations was evaluated in a regression model including the same
covariates as in the main model with an interaction term SNP ×
local ancestry.
Peakwise independent significant SNPs identified in Mexican
Americans were replicated in Puerto Ricans, and those identified in Puerto Ricans were assessed in Mexican Americans.
Additional validation was sought in non-Hispanic/Latino participants with asthma, including 1101 African Americans from the
Study of African Americans, Asthma, Genes and Environments,
1250 Singaporean Chinese from the Singapore Cross Sectional
Genetic Epidemiology Study and 941 Europeans from several
studies: the MEchanism underlying the Genesis and evolution
of Asthma study, the Genomics and Metagenomics of Asthma
Severity study, the Children, Allergy, Milieu, Stockholm, Epidemiology study and the Infancia and Medio Ambiente study.
Details of studies included in the replication are described in
online supplemental material and online supplemental table E1.
Fine-mapping of rare variants (MAF <1%) was conducted
using the SKAT-
O test22 analysing 1-
kilobase (kb) sliding
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windows with 500 bp increments within the admixture mapping
peak limits. The threshold of significance was defined based on
Storey q23 <0.05.

Methylation profiling and QC

DNA methylation from whole blood was profiled using the
Illumina Infinium HumanMethylation450 BeadChip or the
Infinium EPIC BeadChip arrays. QC is detailed in online supplemental material. Briefly, low-quality probes and samples, outliers
of DNA methylation and samples with sex discordance or mixed
genotype distributions on the control SNP probes were excluded.
Standard background correction, dye-bias correction, interarray
normalisation, and probe-type bias adjustment were conducted,
and beta values were transformed to M-values.

RNA sample processing, sequencing and QC

Total RNA was quantified using the Quant-iT RiboGreen RNA
Assay Kit and normalised for library preparation with the Illumina TruSeq Stranded mRNA Sample Preparation Kit. Libraries
were sequenced according to the manufacturer’s protocols
using the HiSeq 4000 system (Illumina). Sample processing and
QC are detailed in online supplemental material. Expression
values were normalised across samples using an inverse normal
transformation.

Functional assessment of associated SNPs

Quantitative trait loci (QTL) analyses in data from whole blood
were conducted separately in Mexican American and Puerto
Rican participants with asthma from GALA II for those CpG
sites or genes with a transcription start site located within
1 Mb of the significant SNPs. Linear regression models were
adjusted for exacerbations status, age, sex, treatment category,
and genetic ancestry. Cis-expression QTL (eQTL) analyses were
adjusted by the top 60 PEER factors,24 and cis-methylation
QTL (meQTL) models by cell-type heterogeneity and methylation batch. The population sub-group results were then meta-
analysed. In silico evidence of functional effects of the variant
on gene expression and DNA methylation was assessed using the
Genotype-Tissue Expression (GTEx) V.8 Portal,25 PhenoScanner
V.2,26 Open Targets Genetics27, and the Genetics of DNA Methylation Consortium (GoDMC).28 Chromatin interactions were

determined using CHiCP.29 Gene expression was inspected using
the GTEx Portal25 and REALGAR.30

RESULTS
Discovery sample characteristics
A total of 820 out of 1124 Puerto Ricans had exacerbations in the
last 12 months (72.9%), while 223 out of 625 Mexican Americans reported exacerbations for the same period (35.7%). Most
of the exacerbators among Puerto Ricans and non-exacerbators
among both ethnic subgroups were in the lowest treatment category, while the distribution in Mexican American exacerbators
was more balanced. Moreover, no significant differences in
global ancestry were detected between exacerbators and non-
exacerbators (p>0.05) (table 1).

Stratified admixture mapping
Genomewide significant associations were found between
Indigenous American ancestry and severe asthma exacerbations
at chromosomes 3p13 and 13q13.2 in Puerto Ricans (table 2,
figure 1A, online supplemental figure E2 in online supplemental
material) (p≤4.33×10−5, accounting for 1154 ancestry blocks).
The most significant association at chromosome 3p13 corresponded to rs4677148, where Indigenous American ancestry
was associated with lower odds of exacerbations (OR: 0.57,
95% CI 0.44 to 0.74, p=2.55×10−5), while European ancestry
was associated with a higher odds of having exacerbations (OR:
1.40, 95% CI 01.16 to 1.94, p=1.82×10−3) but no significant
association with African ancestry was detected (p>0.05). The
strongest association with the odds of severe exacerbations at
13q13.2 was located at rs10514839 (OR: 2.18, 95% CI 1.55 to
3.06, p=6.56×10−6), whereby European or African ancestry
showed no association.
Among Mexican Americans, we identified one admixture
mapping peak at chromosome 5q32, whereby Indigenous American ancestry was genomewide significantly associated with the
odds of severe exacerbations (p≤4.51×10−5, accounting for
1107 ancestry blocks) (table 2, figure 1B, online supplemental
figure E3). The most significant association in the region was
located at rs10477350, where Indigenous American ancestry was
associated with greater odds of exacerbations (OR: 1.73, 95% CI

Table 1 Characteristics of the asthma participants recruited between 2006 and 2014 for the Genes-Environments and Admixture in Latino
Asthmatics (GALA II) study and included in the current study
Puerto Ricans (N=1124)
Exacerbators

Non-exacerbators

Number of individuals

820

304

Sex (% male)

443 (54.0)

160 (52.6)

Age, mean+SD (years)

12.2±3.2

13.8±3.6

Mexican Americans (N=625)
P value
7.27×10–1

Non exacerbators

223

402

P value

129 (57.8)

226 (56.2)

7.57×10–1

1.83×10

–11

12.2±3.2

13.2±3.4

6.16×10–4

–1

38.6±14.7

40.0±13.5

3.03×10–1

4.6±2.2

5.0±3.3

3.03×10–1

56.7±15.2

55.0±14.2

2.00×10–1

European ancestry, mean±SD (%)

62.6±10.7

63.2±10.5

5.45×10

African ancestry, mean±SD (%)

23.5±11.7

26.7±11.4

1.57×10–1

Indigenous American ancestry, mean±SD (%)

Exacerbators

–1

13.8±3.93

14.3±4.8

1.16×10

353 (43.0)

227 (74.7)

8.27×10–21

Treatment category, n (%)
 Step 1

53 (23.7)

185 (46.0)

6.57×10–8

–7

86 (38.6)

131 (32.6)

1.57×10–1

84 (37.7)

86 (21.4)

1.82×10–5

 Step 2

239 (29.1)

41 (13.5)

1.07×10

 Step 3

228 (27.9)

36 (11.8)

3.23×10–8

For continuous variables, the mean and SD are displayed, and Mann-Whitney-Wilcoxon test was applied for the comparison of exacerbators versus non-exacerbators. For
categorical variables, the number and proportion of subjects in each category are shown and a χ2 test was applied for the comparison of exacerbators versus non-exacerbators.
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Table 2

Significant admixture mapping peaks identified in Mexican Americans and Puerto Ricans from GALA II (2006–2014)

Ethnicity/ancestry

Chr. band

Start (Bp)*

End (Bp)*

Peak size (Kb)

rsID†

OR (95% CI)

P value

Puerto Rican/Indigenous American

3p13

72 283 579

72 585 953

302

rs4677148

0.57 (0.44 to 0.74)

2.55×10–5

13q13.2

34 471 415

35 919 337

1448

rs10514839

2.18 (1.55 to 3.06)

6.56×10–6

5q32

147 809 331

147 911 637

102

rs10477350

1.73 (1.34 to 2.24)

3.23×10–5

Mexican American/Indigenous American

*Coordinates are referred to the human reference genome assembly GRCh38.
†Genetic variant with the minimum association p value within the peak.
Bp, base pairs; Chr, chromosome; iSNPs, independent single nucleotide polymorphisms; Kb, kilobases; rsID, reference single nucleotide polymorphism identifier.

1.34 to 2.24, p=3.23×10−5) and European ancestry with lower
odds (OR: 0.60, 95% CI 0.46 to 0.78, p=1.46×10−4).
No genomewide significant associations were found between
severe asthma exacerbations and African or European ancestry
in both ethnic subgroups (online supplemental figure E4). Moreover, a meta-analysis of both ethnic subgroups did not yield any
additional admixture mapping peak at genomewide significant
level.

Fine-mapping analyses

We next performed fine mapping of common variants via allelic
association testing (table 3, online supplemental table E2).
We found a region in the admixture mapping peak at 5q32,
where genetic variation was significantly associated with severe
asthma exacerbations in Mexican Americans after accounting
for the number of variants tested within the peak. Specifically,
four independent variants were associated with severe exacerbations (figure 2A). The minor alleles of SNPs rs1144986
(C5orf46) and rs35439318 (SCGB3A2/CTC-327F10.1) were
associated with lower odds of having exacerbations: OR for G
allele: 0.43, 95% CI 0.28 to 0.66, p=9.45×10−5 and OR for C
allele: 0.51, 95% CI 0.34 to 0.74, p=5.26×10−4, respectively.
Moreover, the A alleles of rs7704889 (C5orf46/EEF1GP2)

Figure 1 Manhattan plot for the admixture mapping results of severe
exacerbations in participants with asthma from GALA II (2006–2014).
(A) Association results for Indigenous American ancestry in Puerto
Ricans. (B) Association results for Indigenous American ancestry in
Mexican Americans. The association with local ancestry is represented
as −log10 p value on the y-axis along the chromosomes (x-axis). The
threshold for significance (grey line) was defined as p<0.05/sum of
the two largest values for the effective number of ancestry blocks:
p≤4.33×10−5 in Puerto Ricans, accounting for 1154 ancestry blocks
(African: 560, European: 594, Native American: 432); and p≤4.51×10−5
in Mexican Americans, accounting for 1107 ancestry blocks (African:
637, European: 470, Native American: 431).
4

and rs10035432 (SCGB3A2/CTC-327F10.1) were associated
with higher odds of exacerbations: OR: 1.58, 95% CI 1.23
to 2.11, p=4.00×10−4 and OR: 1.61, 95% CI 1.23 to 2.11,
p=4.82×10−4, respectively. No significant associations were
detected in any of the regions in Puerto Ricans.
The stepwise addition of the independent SNPs as covariates
to the regression model that tested the association of the lead
ancestry SNP with severe asthma exacerbations revealed that the
SNPs accounted for the 5q32 peak since the association of local
ancestry became non-significant (online supplemental table E3).
Moreover, the association of the SNPs revealed by fine-mapping
and severe exacerbations remained significant after additional
adjustment by local ancestry, and no significant interaction
with local ancestry was found (online supplemental table E4).
To assess the robustness of the associations to socioeconomic
and clinical factors, we performed sensitivity analyses with
adjustment by secondhand smoking exposure, insurance status,
income quartile, maternal education and obesity, confirming that
the effects were not explained by these factors (online supplemental table E5).
We next assessed whether the independent variant replicated among Hispanics/Latino subgroups. In Puerto Ricans, the
SNP rs1144986 (OR for G allele: 0.79, 95% CI 0.62 to 1.00,
p=4.94×10−2) had consistent effects compared with Mexican
Americans. In the meta-analysis of Hispanics/Latinos, the G allele
of rs1144986 showed a protective effect over exacerbations
(OR: 0.60, 95% CI 0.33 to 1.08, p=1.61×10−4, Cochran’s Q
p=1.40×10−2). Moreover, an analysis in 1462 Mexican Americans and 2346 Puerto Ricans revealed that this SNP was not
associated with the underlying asthma susceptibility at p<0.05
(online supplemental table E6).
The SNP that showed significant and consistent effects in
Hispanic/Latino subgroups (rs1144986) was assessed for valiHispanic/Latino populations. However, no
dation in non-
association was found with severe exacerbations (p>0.05) in
Singaporean Chinese, African Americans or Spanish individuals,
or with less severe exacerbations, including school absences in
421 Swedish children or wheezing in the last year in 100 Spanish
individuals (online supplemental table E7).
We next tested the association of rare variants with severe
asthma exacerbations. No significant associations were found
within the admixture mapping peaks identified in either Puerto
Ricans or Mexican Americans (q>0.05).

Assessment of functional effects of the genetic variants
The effect of rs1144986 on DNA methylation in whole blood
from Hispanic/Latino participants with asthma was evaluated for 196 CpG sites located within ±1 Megabase (Mb) of
the SNP. The SNP rs1144986 was significantly associated with
three probes annotated to DPYSL3, being cg04833034, at
57.4 kb of DPYSL3, the most significant CpG (p=5.17×10−6,
q=3.41×10−3). Moreover, associations for CpGs at PPP2R2B
Herrera-Luis E, et al. Thorax 2022;0:1–9. doi:10.1136/thoraxjnl-2022-218755
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1.45×10–3†
0.66 (0.41 to 1.08)
Association p values<0.05 are shown in bold.
*Coordinates are referred to the human reference genome assembly GRCh38.
†A random effect model was applied since heterogeneity was found between populations (Cochran’s Q p value<0.05).
A1, effect allele; A2, non-effect allele; Bp, base pairs; EAF, effect allele frequency; rsID, reference single nucleotide polymorphism identifier.

0.22
SCGB3A2/CTC-327F10.1
147 862 111
rs35439318

C/T

0.15

0.51 (0.34 to 0.74)

5.26×10–4

0.83 (0.65 to 1.05)

1.27×10–1

5.93×10–3†
1.28 (0.81 to 2.00)
0.21
SCGB3A2/CTC-327F10.1
147 855 193
rs10035432

A/G

0.26

1.61 (1.23 to 2.11)

4.82×10

1.02 (0.81 to 1.29)

8.72×10

6.57×10–3†
1.23 (0.77 to 1.98)

–1

0.42

–4

C5orf46/EEF1GP2
147 911 637
rs7704889

A/G

147 883 415
rs1144986

C5orf46

0.54

1.58 (1.23 to 2.03)

4.00×10

0.97 (0.79 to 1.20)

7.94×10

1.61×10–4†
0.60 (0.33 to 1.08)

–1

0.22

–4

P value

G/A

0.13

0.43 (0.28 to 0.66)

9.45×10

0.79 (0.62 to 1.00)

4.94×10

–2
–5

Meta-analysis

OR (95% CI)
p value
OR (95% CI)

Puerto Ricans

EAF
P value
OR (95% CI)

Mexican Americans

EAF
Closest gene
A1/A2
Position (Bp)*
rsID

Association results of independent genetic variants at chromosome 5 that were peak-wise significantly associated with severe asthma exacerbations in Hispanics/Latinos from GALA II (2006–
Table 3
2014)

Figure 2 Locus zoom for the fine-mapping results displaying
the region around the most significant signals at 5q32 in Mexican
Americans with asthma from GALA II (2006–2014). The statistical
significance of association results (−log10 p value) is represented for
each single nucleotide polymorphism (SNP) as a dot (left y-axis) by
chromosome position (x-axis). SNPs are colour-coded to show their
linkage disequilibrium (LD) with the most significant SNP based on the
pairwise r2 values from Mexican Americans. The peak-wise significance
threshold is represented as a dashed blue line.
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and C5orf46 were also observed (table 4). Notably, the associations with cg24686270 and cg10930901 were replicated in the
GoDMC results28 (p=1.1×10−139 and 7.1×10–29, respectively).
DPYSL3 expression in bronchial epithelial cells was found to
be increased in severe asthma in publicly available gene expression data sets of asthma participants (online supplemental figure
E5). Additionally, the meQTL rs1144986 showed evidence of
chromatin interaction with C5orf46 in lymphoblastoid cells
(CHiCAGO score=11.7) and association with H3K4me1 histone
marks in blood (online supplemental table E4). Notably, none of
the significant CpGs regulated the expression of nearby genes in
whole blood in a subset of 126 Puerto Ricans and 40 Mexicans
with DNA methylation and gene expression data available at a
false discovery rate-adjusted p<0.05 (online supplemental table
E8).
The effect of rs1144986 over the expression of genes with
transcription start site within ±1 Mb was assessed. From the
5 SNP-
gene pairs, the SNP rs1144986 showed significant
associations with gene expression of SCGB3A2 at q<0.05 in
whole blood (p=6.62×10−22; q=6.62×10−20), and the association was also validated in blood according to the GTEx
(p=5.1×10−10),25 PhenoScanner and Open Targets Genetics
(minimum p=3.3×10−310).26 27

Discussion

This admixture mapping analysis of severe asthma exacerbations in Hispanic/Latino children with asthma identified
several genomic regions in which local Indigenous American
or European ancestry was associated with severe asthma exacerbations in Puerto Ricans and Mexican Americans. Although
fine mapping in Puerto Ricans revealed no significant variants,
we found four independent SNPs explaining the admixture
mapping peak for Indigenous American ancestry at chromosome
5q32 in Mexican Americans, including rs1144986 (C5orf46),
which showed significant consistent effects among Hispanic/
5
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SCGB3A2
147 870 682
ENSG00000164265
rs1144986 - eQTL

*A fixed effect model was applied since no heterogeneity was found between populations (Cochran’s Q p value>0.05).
†Chromosomal positions referred to the genome assembly GRCh38. For CpG sites, the location of the CpG is stated. For genes, the location of the transcription start site is shown.
‡The SNP did not meet the genotype inclusion criteria for the individuals profiled with the EPIC array.
Coef, regression coefficient estimate; NA, not available/applicable; PQ, Cochran’s Q-test p value; Q, Q-value; SE, standard error of the regression coefficient estimate.
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Significant results from the QTL mapping in Hispanics/Latinos from GALA II (2006–2014)
Table 4
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Figure 3 Gene expression levels of SCGB3A2 in whole blood by
genotype at rs1144986 in participants with asthma from GALA II
(2006–2014). (A) Mexican Americans and (B) Puerto Ricans.
Latino subgroups. Interestingly, none of the four loci was associated with asthma exacerbations in non-Hispanic/Latino populations, suggesting ethnic-specific effects shared among Hispanic/
Latino subgroups. This could be explained, at least partially,
due to differences in allele frequency and ethnic background.
For example, at 5q32, Indigenous American ancestry was associated with higher odds of exacerbations in Mexican Americans, and the risk allele (A) of rs1144986 was more common
among Native Americans (frequency=98%) and Mexicans
(frequency=87%) than in Puerto Ricans (frequency=78%) or
Europeans (frequency=67%) (online supplemental table E4,
E6). The fact that Indigenous American ancestry is around 2%
in African Americans,31 which could contribute to the lack of
validation of these genetic variants despite the higher risk allele
frequency (89%) observed.
An analysis of functional effects revealed that rs1144986 altered
DNA methylation of several nearby genes, including DPYSL3.
The protein DPYSL3 is involved in cytoskeleton remodelling by
participating in the signalling of class 3 semaphorins. While the
role of DPYSL3 in asthma is unclear, it is coexpressed with genes
involved in airway type 2 inflammation.32 However, DPYSL3
expression in whole blood data from Hispanics/Latinos could
not be evaluated due to low levels or lack of expression, consistently with the GTEx data.25 Additionally, the protective allele of
rs1144986 increased SCGB3A2 expression in blood (figure 3),
although SCGB3A2 is predominantly expressed in the lung.25
SCGB3A2 is involved in lung development33 and has shown an
anti-inflammatory role in mice.34–37 More recently, the role of
secretoglobins as airway immunoregulators is gaining interest.38
Lung expression levels of proinflammatory cytokines, IL-4, IL-5
and IL-13, are lower in ovalbumin-induced mice pretreated with
SCGB3A2 compared with those not treated with it.36 37 Plasma
SCGB3A2 levels are decreased in severe asthma,39 and SCGB3A2
polymorphisms have been associated with asthma susceptibility.40 In human bronchial epithelial cells, SCGB3A2 decreased
airway inflammation inhibiting the extracellular signal-regulated
kinase (ERK) and the c-
Jun N-
terminal kinase (JNK) activation.41 In lung cancer, SCGB3A2 induced pyroptotic cell death.
Interestingly, participants with higher SCGB3A2 gene expression
manifested higher survival rates.42 Moreover, SCGB3A2 shows
antifibrotic activity through increased expression of STAT1
Herrera-Luis E, et al. Thorax 2022;0:1–9. doi:10.1136/thoraxjnl-2022-218755
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phosphorylation and SMAD7 expression,43 44 hence, decreasing
SMAD2/3 phosphorylation, which attenuates the TGFβ signalling,44 a key pathway implicated in airway remodelling,45 allergic
airway inflammation46 and drug response in asthma.47 Taken
together, this evidence suggests that these genes may be involved
in susceptibility to asthma exacerbations and merit further
exploration to understand their specific role.
Our study has several strengths and limitations. We focused
on minority populations at high risk of asthma that have undergone distinct historical processes and show differential asthma
exacerbations rates. Although we identified several regions in
which local ancestry was associated with severe exacerbations,
analysing two different Hispanic/Latino subgroups may have
hindered our power to detect associations. Specifically, this
could have affected the identification of SNPs in the regions
where Indigenous American ancestry was associated with exacerbations in Puerto Ricans, as this ancestral population has a
smaller contribution to their genetic background compared with
Mexican Americans. Our study was especially underpowered to
detect an association of rare variants. Specifically, assuming 30%
of causal risk variants, we were only powered at >80% to detect
rare variant signals with a maximum OR ≥18 in Puerto Ricans,
likely due to the larger sample size compared with Mexicans.
Moreover, although genetic signals identified by fine-mapping
exceeded the respective peakwise threshold of significance
(table 2, online supplemental table E2), none would have
exceeded a stringent correction for the total number of independent variants tested in the discovery stage (p=0.05/1 977
SNPs=2.53×10−5). Furthermore, we also sought to determine
whether these genetic variants may exert the same effects in
non-Hispanic/Latino populations. The fact that none of the variants was validated in non-Hispanics/Latinos suggests that they
could exhibit ethnic-specific effects. We attempted to overcome
these limitations by performing functional analyses to reveal the
effects of the variant identified on whole blood gene expression
and DNA methylation in Hispanics/Latinos. Although whole
blood epigenetic and transcriptional signals may capture the
inflammatory component related to specific blood cell types,
future studies in airway tissues should be required due to the
modest cross-tissue replication described in asthma.48 However,
given that we analysed a mixed cell-type tissue, our analyses
were adjusted by blood cell-type heterogeneity to overcome this
limitation.48 Despite this, other epigenetic mechanisms known to
be involved in asthma (eg, histone modifications or miRNAs49)
could also underlie the functional role of the genetic variation.
Moreover, chromatin interactions were evaluated in silico using
a publicly available database due to the lack of experimental data
from Hispanic/Latino participants with asthma. Therefore, the
role of these loci in asthma exacerbations should be explored in
future studies using cell lines from asthma participants or animal
models of this disease.
In summary, we leveraged local ancestry to identify genomic
regions that contribute to severe asthma exacerbations in
Hispanic/Latinos. Indigenous American ancestry was associated
with asthma exacerbation risk at 5q32-q33.1 and novel association of a genetic variant with severe asthma exacerbations with
a potential population-specific effect was uncovered. Moreover,
these variants had functional effects on SCGB3A2 gene expression and DPYSL3 DNA methylation, two genes that are plausibly
implicated in severe exacerbations.
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